Zum Inhalt

Variables determining the development of colistin-associated renal impairment

  • 01.12.2016
  • original article
Erschienen in:

Summary

Aim

The aim of this study was to identify the predictors of acute renal injury associated with colistin treatment.

Methods

The patients who received treatment with colistin for more than 3 days were included in this retrospective cohort study. Acute renal injury was defined by the RIFLE (Risk Injury Failure Loss End stage renal disease) criteria. Patients whose serum creatinine levels increased at least 1.5-fold compared with baseline value were considered as cases with renal injury. The independent variables determining the development of acute renal injury were investigated by survival analysis.

Results

A total of 112 cases [67 (59.8 %) were male, median age 64 (range: 18–93) years] were included in the study. Acute renal injury occurred in 66 (58.9 %) patients. Renal injury developed in first 7 days of the colistin therapy in 52 (78.8 %) cases and at day 8–23 in 14 (21.2 %) cases. On the day with highest levels of creatinine, 25 (22.3 %), 17 (15.2 %), and 33 (29.5 %) cases were in ‘Risk’, ‘Injury’, and ‘Failure’ group, respectively, according to RIFLE criteria. We identified three independent risk factors predicting acute colistin-induced renal injury: advanced age, low serum albumin levels, and high serum total bilirubin levels [odds ratio (confidence interval) = 1.022 (1.006–1.037), 0.643 (0.415–0.994), and 1.129 (1.014–1.257), respectively].

Conclusions

The advanced age, low serum albumin levels, and high serum total bilirubin levels are independent risk factors for colistin-induced nephrotoxicity.
Titel
Variables determining the development of colistin-associated renal impairment
Verfasst von
Bahadır Ceylan, MD
Müdür Taniş
Muhammed Emin Akkoyunlu
Ahmet Çınar
Ayşe Ruhkar Kurt
Yasemin Akkoyunlu
Didem Ozkan
Hatice Kutbay Ozcelik
Turan Aslan
Muzaffer Fincancı
Şule Vatansever
Kadir İdin
Emine Guler
Harun Uysal
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 8/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0773-z
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.